Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX7 | Q99572 | 1/20 | 0.34 |
| ▸ | PRMT1 | Q99873 | 11/20 | 0.33 |
| ▸ | PRMT6 | Q96LA8 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22275430 | 0.81 | PRMT1 (0.31) | PRMT1 | |
| SCHEMBL24054093 | 0.81 | P2RX7 (0.37) | P2RX7 | |
| SCHEMBL25786568 | 0.81 | PRMT1 (0.33) | PRMT1 | |
| SCHEMBL30955794 | 0.77 | POLB (0.36) | P2RX7PRMT1 | |
| SCHEMBL22275223 | 0.77 | — | — | |
| SCHEMBL22275609 | 0.76 | — | — | |
| SCHEMBL22275429 | 0.76 | TGFBR1 (0.34) | PRMT1PRMT6 | |
| SCHEMBL23535514 | 0.75 | THRB (0.35) | — | |
| SCHEMBL22275233 | 0.72 | TGFBR1 (0.32) | PRMT1PRMT6 | |
| SCHEMBL22412889 | 0.72 | HRH3 (0.36) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11691989-B2 | Macrocyclic indoles as Mcl-1 inhibitors | ASCENTAGE PHARMA (SUZHOU) CO., LTD. (CN) | 2023-07-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11691989-B2 | Macrocyclic indoles as Mcl-1 inhibitors | MCL1, BCL2A1, BCL2L1 | P2RX7 4618/4885PRMT1 76/4885PRMT6 309/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.